These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23661160)

  • 1. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
    Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
    Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.
    Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
    J Immunol; 2012 Sep; 189(5):2656-64. PubMed ID: 22844125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
    Hank JA; Gan J; Ryu H; Ostendorf A; Stauder MC; Sternberg A; Albertini M; Lo KM; Gillies SD; Eickhoff J; Sondel PM
    Clin Cancer Res; 2009 Sep; 15(18):5923-30. PubMed ID: 19737959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
    Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Immunocytokine and
    Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM
    Front Immunol; 2021; 12():668307. PubMed ID: 34489927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
    Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
    Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
    Neal ZC; Imboden M; Rakhmilevich AL; Kim KM; Hank JA; Surfus J; Dixon JR; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2004 Jan; 53(1):41-52. PubMed ID: 14504825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
    Nguyen R; Zhang X; Sun M; Abbas S; Seibert C; Kelly MC; Shern JF; Thiele CJ
    Clin Cancer Res; 2022 Sep; 28(17):3785-3796. PubMed ID: 35802683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
    Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
    Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
    Yamane BH; Hank JA; Albertini MR; Sondel PM
    Expert Opin Investig Drugs; 2009 Jul; 18(7):991-1000. PubMed ID: 19548853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
    Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
    Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
    Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
    Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
    Shusterman S; London WB; Gillies SD; Hank JA; Voss SD; Seeger RC; Reynolds CP; Kimball J; Albertini MR; Wagner B; Gan J; Eickhoff J; DeSantes KB; Cohn SL; Hecht T; Gadbaw B; Reisfeld RA; Maris JM; Sondel PM
    J Clin Oncol; 2010 Nov; 28(33):4969-75. PubMed ID: 20921469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
    Delgado DC; Hank JA; Kolesar J; Lorentzen D; Gan J; Seo S; Kim K; Shusterman S; Gillies SD; Reisfeld RA; Yang R; Gadbaw B; DeSantes KB; London WB; Seeger RC; Maris JM; Sondel PM
    Cancer Res; 2010 Dec; 70(23):9554-61. PubMed ID: 20935224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
    Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
    Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.